Item 5. Other Information
Item 5. Other Information.
Rule 10b5-1 Trading Plans
During the quarter ended March 31, 2025, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K).
28
Table of Contents
Item 6. Exhibits.
10.1
Amendment to Building D Lease Agreement, dated April 10, 2024, between Myriad Genetics, Inc. and ATP SLC D, LLC (incorporated by reference to Exhibit 10.4.2 to the Company’s Annual Report on Form 10-K, File No. 000-26642, filed with the SEC on February 28, 2025).
10.2
Lease Agreement, dated December 1, 2012, by and between Assurex Health, Inc. and the City of Mason, Ohio (incorporated by reference to Exhibit 10.6.1 to the Company’s Annual Report on Form 10-K, File No. 000-26642, filed with the SEC on February 28, 2025).
10.3
Fifth Addendum to Lease Agreement, dated February 20, 2025, between Assurex Health, Inc. and the City of Mason, Ohio (incorporated by reference to Exhibit 10.6.2 to the Company’s Annual Report on Form 10-K, File No. 0-26642, filed with the SEC on February 28, 2025).
10.4+
Amended and Restated Employment Agreement, dated February 24, 2025, between Myriad Genetics, Inc. and Samraat S. Raha (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8 -K, File No. 00 0-26642, filed with the SEC on February 2 4 , 2025).
10.5+
Chief Executive Officer Severance and Change of Control Agreement, dated February 24, 2025, by and between Myriad Genetics, Inc. and Samraat S. Raha (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, File No. 00 0-26642, filed with the SEC on February 24, 2025 ).
10.6+
Employment Agreement, dated February 24, 2025, by and between the Company and Mark S. Verratti (incorporated by reference to Exhibit 10. 3 to the Company’s Current Report on Form 8-K, File No. 00 0-26642, filed with the SEC on February 24, 2025 ).
10.7+
Severance and Change of Control Agreement, dated February 24, 2025, by and between the Company and Mark S. Verratti (incorporated by reference to Exhibit 10. 4 to the Company’s Current Report on Form 8-K, File No. 00 0-26642, filed with the SEC on February 24, 2025 ).
10.8
Consulting Agreement, dated February 24, 2025, by and between the Company and Paul J. Diaz (incorporated by reference to Exhibit 10. 5 to the Company’s Current Report on Form 8-K, File No. 00 0-26642, filed with the SEC on February 24, 2025 ).
10.9+
Restricted Stock Unit Agreement , dated May 1, 2025, by and between t he Company and Brian Donnelly .
10.10+
Performance-Based Restricted Stock Unit Agreement, dated May 1, 2025, by and between the Company and Brian Donnelly .
31.1 Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.
32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).
101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 has been formatted in Inline XBRL.
+ Management contract or compensatory plan or arrangement.
29
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MYRIAD GENETICS, INC.
Date: May 7, 2025 By: /s/ Samraat S. Raha
Samraat S. Raha
President and Chief Executive Officer
(Principal executive officer)
Date: May 7, 2025 By: /s/ Scott J. Leffler
Scott J. Leffler
Chief Financial Officer
(Principal financial officer)
Date: May 7, 2025 By: /s/ Natalie Munk
Natalie Munk
Chief Accounting Officer
(Principal accounting officer)
30
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.